SCHEMBL422422

SCHEMBL422422

CC(CCCCO)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 1/20 0.56
LTA4H P09960 1/20 0.55
GABRR1 P24046 2/20 0.52
CYP1A2 P05177 1/20 0.52
ACE2 Q9BYF1 1/20 0.52
TBXAS1 P24557 2/20 0.43
CA1 P00915 2/20 0.41
GPR84 Q9NQS5 2/20 0.39
CHRM1 P11229 1/20 0.39
AKR1A1 P14550 1/20 0.39
CHRM3 P20309 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
ADRA1A P35348 1/20 0.39
HRH1 P35367 1/20 0.39
DRD3 P35462 1/20 0.39
SLC6A3 Q01959 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13554886 1.00 BLM (0.56) BLMLTA4HGABRR1CYP1A2ACE2
SCHEMBL8984582 0.98 ACE2 (0.55) BLMLTA4HGABRR1CYP1A2ACE2
SCHEMBL5074983 0.98 ACE2 (0.55) BLMLTA4HGABRR1CYP1A2ACE2
SCHEMBL8984494 0.98 ACE2 (0.55) BLMLTA4HGABRR1CYP1A2ACE2
SCHEMBL1875589 0.98 ACE2 (0.55) BLMLTA4HGABRR1CYP1A2ACE2
SCHEMBL8984664 0.98 ACE2 (0.55) BLMLTA4HGABRR1CYP1A2ACE2
SCHEMBL8984408 0.98 ACE2 (0.55) BLMLTA4HGABRR1CYP1A2ACE2
SCHEMBL8230933 0.98 ACE2 (0.55) BLMLTA4HGABRR1CYP1A2ACE2
SCHEMBL3685397 0.98 ACE2 (0.55) BLMLTA4HGABRR1CYP1A2ACE2
SCHEMBL16536902 0.98 ACE2 (0.55) BLMLTA4HGABRR1CYP1A2ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134315-B1 TATTOO-REMOVING COMPOSITION SK AGELESS CONCEPT GMBH (DE) 2016-11-09 EP claimed
US-20100119466-A1 TATTOO-REMOVING COMPOSITION SK AGELESS CONCEPT GMBH (DE) 2010-05-13 US claimed
EP-2134315-A1 TATTOO-REMOVING COMPOSITION SK ageless-concept GmbH (DE) 2009-12-23 EP claimed
WO-2008128514-A1 TATTOO-REMOVING COMPOSITION FAGRON GROUP B.V. (NL) 2008-10-30 WO claimed
EP-1000076-A1 HEXADECASACCHARIDE-PROTEIN CONJUGATE VACCINE FOR $i(SHIGELLA DYSENTERIAE) TYPE 1 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2000-05-17 EP claimed
WO-1999003871-A1 HEXADECASACCHARIDE-PROTEIN CONJUGATE VACCINE FOR SHIGELLA DYSENTERIAE TYPE 1 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1999-01-28 WO claimed
US-11795241-B2 Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same CYDEX PHARMACEUTICALS, INC. (US) 2023-10-24 US disclosed
CN-114044886-B Production method of polycaprolactone 青岛科技大学 2023-08-29 CN disclosed
CN-113993914-B Amide compound, polymerizable composition, cured product, and method for producing same 株式会社ADEKA 2023-05-09 CN disclosed
US-20210147582-A1 FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2021-05-20 US disclosed
US-10851184-B2 Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same CYDEX PHARMACEUTICALS, INC. (US) 2020-12-01 US disclosed
US-10800861-B2 Alkylated cyclodextrin compositions and processes for preparing and using the same CYDEX PHARMACEUTICALS, INC. (US) 2020-10-13 US disclosed
US-10633462-B2 Manufacturing process for cyclodextrin derivatives CYDEX PHARMACEUTICALS, INC. (US) 2020-04-28 US disclosed
EP-0680522-A1 METALLIZED POLY(LACTIC ACID) FILMS. DU PONT (US) 1995-11-08 EP disclosed
WO-1995007919-A1 METHOD FOR DOSING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 1995-03-23 WO disclosed
US-5391723-A Oligonucleotide conjugates NEORX CORPORATION (US) 1995-02-21 US disclosed
US-5382617-A Heat resistant polymers with boron oxide E. I. DU PONT DE NEMOURS AND COMPANY (US) 1995-01-17 US disclosed
WO-1994017220-A1 METALLIZED POLY(LACTIC ACID) FILMS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1994-08-04 WO disclosed
CN-1016778-B spiro-substituted glutaric acid monoamides PFIZER LTD (GB) 1992-05-27 CN disclosed
US-4140712-A 20-Hydroxy-prostaglandins ONO PHARMACEUTICAL COMPANY (JP) 1979-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10633462-B2 Manufacturing process for cyclodextrin derivatives DCXR, AGL, OSTC BLM 3365/4885LTA4H 1526/4885GABRR1 3386/4885
US-11795241-B2 Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same AGPS, DDOST, ALG1 BLM 2076/4885LTA4H 1173/4885GABRR1 2899/4885
US-20210147582-A1 FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME AGPS, DDOST, ALG1 BLM 2076/4885LTA4H 1173/4885GABRR1 2899/4885
US-10800861-B2 Alkylated cyclodextrin compositions and processes for preparing and using the same AGL, AGPS, MGAM BLM 3226/4885LTA4H 729/4885GABRR1 2114/4885
US-10851184-B2 Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same AGPS, DDOST, ALG1 BLM 2076/4885LTA4H 1173/4885GABRR1 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.